Final results of BIRCOV trial (ARB, ACEI, DRi in COVID-19)
Background. The question of the possible effect of the inhibitors of the renin-angiotensin system (iRAS) on hypertensive subjects who fell ill with COVID-19 has been discussed in the literature. SARS-CoV-2 is well-known to use an angiotensin-converting enzyme 2 receptors facilitating virus entry int...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Publishing House Zaslavsky
2021-09-01
|
| Series: | Počki |
| Subjects: | |
| Online Access: | http://kidneys.zaslavsky.com.ua/article/view/239591 |